Literature DB >> 33728540

Anti-inflammatory potential of Empagliflozin.

Markus Pirklbauer1.   

Abstract

Entities:  

Keywords:  Anti-inflammatory potential; Empagliflozin; Human proximal tubulus; Nephroprotection; SGLT2 inhibition

Year:  2021        PMID： 33728540      PMCID： PMC7997819          DOI： 10.1007/s10787-021-00797-9

Source DB:  PubMed          Journal:  Inflammopharmacology        ISSN： 0925-4692            Impact factor:   4.473


× No keyword cloud information.
  35 in total

1.  Empagliflozin suppresses inflammation and protects against acute septic renal injury.

Authors:  Zaid H Maayah; Mourad Ferdaoussi; Shingo Takahara; Shubham Soni; Jason R B Dyck
Journal:  Inflammopharmacology       Date:  2020-06-20       Impact factor: 4.473

Review 2.  Inflammation and renal fibrosis: Recent developments on key signaling molecules as potential therapeutic targets.

Authors:  Wenshan Lv; George W Booz; Yangang Wang; Fan Fan; Richard J Roman
Journal:  Eur J Pharmacol       Date:  2017-12-08       Impact factor: 4.432

3.  Targeting the MCP-1/CCR2 System in diabetic kidney disease.

Authors:  Sara Giunti; Federica Barutta; Paolo Cavallo Perin; Gabriella Gruden
Journal:  Curr Vasc Pharmacol       Date:  2010-11       Impact factor: 2.719

Review 4.  The proximal tubule in the pathophysiology of the diabetic kidney.

Authors:  Volker Vallon
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-01-12       Impact factor: 3.619

5.  Empagliflozin Protects against Diet-Induced NLRP-3 Inflammasome Activation and Lipid Accumulation.

Authors:  Elisa Benetti; Raffaella Mastrocola; Giovanna Vitarelli; Juan Carlos Cutrin; Debora Nigro; Fausto Chiazza; Eric Mayoux; Massimo Collino; Roberto Fantozzi
Journal:  J Pharmacol Exp Ther       Date:  2016-07-20       Impact factor: 4.030

6.  Interleukin-1-receptor antagonist in type 2 diabetes mellitus.

Authors:  Claus M Larsen; Mirjam Faulenbach; Allan Vaag; Aage Vølund; Jan A Ehses; Burkhardt Seifert; Thomas Mandrup-Poulsen; Marc Y Donath
Journal:  N Engl J Med       Date:  2007-04-12       Impact factor: 91.245

7.  Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease.

Authors:  Hiddo J L Heerspink; Paul Perco; Skander Mulder; Johannes Leierer; Michael K Hansen; Andreas Heinzel; Gert Mayer
Journal:  Diabetologia       Date:  2019-04-17       Impact factor: 10.122

8.  Effect of the monocyte chemoattractant protein-1/CC chemokine receptor 2 system on nephrin expression in streptozotocin-treated mice and human cultured podocytes.

Authors:  Elena Tarabra; Sara Giunti; Federica Barutta; Gennaro Salvidio; Davina Burt; Giacomo Deferrari; Roberto Gambino; Daniela Vergola; Silvia Pinach; Paolo Cavallo Perin; Giovanni Camussi; Gabriella Gruden
Journal:  Diabetes       Date:  2009-07-08       Impact factor: 9.461

9.  Nlrp3-inflammasome activation in non-myeloid-derived cells aggravates diabetic nephropathy.

Authors:  Khurrum Shahzad; Fabian Bock; Wei Dong; Hongjie Wang; Stefan Kopf; Shrey Kohli; Moh'd Mohanad Al-Dabet; Satish Ranjan; Juliane Wolter; Christian Wacker; Ronald Biemann; Stoyan Stoyanov; Klaus Reymann; Peter Söderkvist; Olaf Groß; Vedat Schwenger; Sascha Pahernik; Peter P Nawroth; Herman-Josef Gröne; Thati Madhusudhan; Berend Isermann
Journal:  Kidney Int       Date:  2014-07-30       Impact factor: 10.612

10.  Urinary epidermal growth factor, monocyte chemoattractant protein-1 or their ratio as predictors for rapid loss of renal function in type 2 diabetic patients with diabetic kidney disease.

Authors:  Bancha Satirapoj; Rattanawan Dispan; Piyanuch Radinahamed; Chagriya Kitiyakara
Journal:  BMC Nephrol       Date:  2018-09-21       Impact factor: 2.388
View more
  3 in total

1.  Empagliflozin-Metformin Combination Has Antioxidative and Anti-Inflammatory Properties that Correlate with Vascular Protection in Adults with Type 1 Diabetes.

Authors:  Miodrag Janić; Matej Cankar; Jan Šmid; Alenka France Štiglic; Aleš Jerin; Mišo Šabovič; Andrej Janež; Mojca Lunder
Journal:  J Diabetes Res       Date:  2022-05-17       Impact factor: 4.061

Review 2.  Empagliflozin Ameliorates Progression From Prediabetes to Diabetes and Improves Hepatic Lipid Metabolism: A Systematic Review.

Authors:  Md Fahad Hossain; Nawsheen A Khan; Afroza Rahman; Mirza Farhana Iqbal Chowdhury; Sadia Bari; Mahfuza A Khan; Ummul Wara Masud; Ummul B Zakia; Shibani P Paul; Nishat Tasnim
Journal:  Cureus       Date:  2022-08-25

3.  Empagliflozin Inhibits IL-1β-Mediated Inflammatory Response in Human Proximal Tubular Cells.

Authors:  Markus Pirklbauer; Sebastian Sallaberger; Petra Staudinger; Ulrike Corazza; Johannes Leierer; Gert Mayer; Herbert Schramek
Journal:  Int J Mol Sci       Date:  2021-05-11       Impact factor: 5.923
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.